(1 - 8 from 8
)
Molecular Partner’s DARPins may help reshape anticancer treatment...
www.startupticker.ch
“The data from this ongoing phase I study are the first demonstration that DARPins can be administered systemically to patients with good tolerability and that sustained exposures over multiple treatment cycles can be achieved,” said Andreas Harstrick, MD, Chief Medical Officer of Molecular Partners.
Myeloma Therapy Candidate MP0250 Shows Positive Interim Trial Results
myelomaresearchnews.com
”We are very pleased with the good initial safety and tolerability data we observed in the first eight patients treated with MP0250 in combination with bortezomib and dexamethasone,” Andreas Harstrick, chief medical officer at Molecular Partners, said in a press release. “We look forward to evaluating ...
sorted by relevance / date